Macquarie Group Limited 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-07 07:44 am Sale |
2024-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
Macquarie Group Limited | 4,259,557 4.900% |
-486,587 (-10.25%) |
Filing |
| 2024-02-14 06:38 am Purchase |
2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
Macquarie Group Limited | 4,746,144 6.310% |
1,190,152 (+33.47%) |
Filing |
| 2023-02-14 3:22 pm Sale |
2022-12-30 | 13G | Travere Therapeutics, Inc. TVTX |
Macquarie Group Limited | 3,555,992 5.540% |
-211,900 (-5.62%) |
Filing |
| 2022-02-14 10:24 am Purchase |
2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
Macquarie Group Limited | 3,767,892 6.150% |
1,003,970 (+36.32%) |
Filing |
| 2021-02-12 08:41 am Purchase |
2020-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
Macquarie Group Limited | 2,763,922 5.410% |
2,763,922 (New Position) |
Filing |